NCT01304433已完成不适用
Evaluation on the Safety Profile of Hydroxyethyl Starch (HES) 130/0.42
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,000
- 试验地点
- 6
- 主要终点
- number of adverse drug reactions
研究概览
简要总结
The study is primarily aimed to collect further data on the safety of the investigational product in a large patient population when used in routine clinical practice in the Asian-Pacific region.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
hydroxyethyl starch (HES) 130/0.42
干预措施: Venofundin 6% / Tetraspan 6% (Drug)
结局指标
主要结局
number of adverse drug reactions
时间窗: up to 48 hours
次要结局
- change in haemodynamics during surgery or intensive care unit stay(up to 48 hours)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
4 期
Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma PatientsHypovolemia Due to Acute Blood LossNCT03338218Fresenius Kabi238
已完成
4 期
Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal SurgeryHypovolaemia Due to Acute Blood LossNCT03278548Fresenius Kabi2,289
招募中
不适用
A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing LossDFNB9Congenital Hearing LossHearing Loss, SensorineuralNCT06722170Yilai Shu24
已完成
3 期
Trial of 6% HES130/0.4HypovolemiaHemorrhageNCT01010022Fresenius Kabi Japan64
已完成
不适用
Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a WoundScarNCT01706848Halscion, Inc.60